OTCPK:PHRX

Stock Analysis Report

Executive Summary

Pharmagen, Inc. distributes specialty drugs to hospitals, acute care facilities, surgery centers, and other healthcare practitioners in the United States.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • Pharmagen has significant price volatility in the past 3 months.
  • Pharmagen's last earnings update was 1957 days ago.
  • Pharmagen is not covered by any analysts.

Share Price & News

How has Pharmagen's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

200.0%

PHRX

-0.3%

US Healthcare

-0.6%

US Market


1 Year Return

53.1%

PHRX

-9.2%

US Healthcare

0.7%

US Market

PHRX outperformed the Healthcare industry which returned -9.1% over the past year.

PHRX outperformed the Market in United States of America which returned 0.7% over the past year.


Share holder returns

PHRXIndustryMarket
7 Day200.0%-0.3%-0.6%
30 Day150.0%2.1%4.9%
90 Day66.7%-0.8%1.7%
1 Year53.1%53.1%-7.8%-9.2%3.0%0.7%
3 Year200.0%200.0%29.7%24.4%44.8%35.4%
5 Year-62.5%-62.5%66.1%56.2%62.0%44.3%

Price Volatility Vs. Market

How volatile is Pharmagen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Pharmagen undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Pharmagen is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Pharmagen has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine Pharmagen's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Pharmagen regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Pharmagen expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Pharmagen has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Pharmagen performed over the past 5 years?

0.1%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Pharmagen has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is Pharmagen's financial position?


In this section we usually analyse Pharmagen's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Pharmagen has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of PHRX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Pharmagen's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is Pharmagen's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Pharmagen's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Pharmagen's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Pharmagen has not reported any payouts.

Unable to verify if Pharmagen's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Pharmagen has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Pharmagen's salary, the management and board of directors tenure and is there insider trading?


CEO

Pharmagen has no CEO, or we have no data on them.


Insider Trading

No 3 month open market individual insider trading information.


Management Team

  • Bach Barch (44yo)

    Founder and Vice Chairman

    • Tenure: 0yrs
    • Compensation: US$150.00k

Board Members

  • Bach Barch (44yo)

    Founder and Vice Chairman

    • Tenure: 0yrs
    • Compensation: US$150.00k

Company Information

Pharmagen, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Pharmagen, Inc.
  • Ticker: PHRX
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: US$775.614k
  • Shares outstanding: 517.08m
  • Website: https://www.pharmageninc.com

Number of Employees


Location

  • Pharmagen, Inc.
  • 9337 Fraser Avenue
  • Silver Spring
  • Maryland
  • 20910
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PHRXOTCPK (Pink Sheets LLC)YesCommon StockUSUSDFeb 2012

Biography

Pharmagen, Inc. distributes specialty drugs to hospitals, acute care facilities, surgery centers, and other healthcare practitioners in the United States. The company sources and distributes specialty drug ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/23 00:27
End of Day Share Price2019/09/20 00:00
Earnings2014/03/31
Annual Earnings2013/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.